Monoclonal antibody treatments in the United States typically cost between $15,000 and $200,000 per year, depending on the condition being treated and the specific drug. Cancer treatments sit at the high end of that range, while drugs for autoimmune conditions and migraine prevention fall lower. What you actually pay out of pocket depends heavily on your insurance, the type of drug, and whether a cheaper biosimilar version is available.
Cost Ranges by Condition
The price tag for monoclonal antibodies varies enormously based on what they’re treating. Cancer therapies are consistently the most expensive category, with an average yearly price of about $96,731 as of 2018. One of the most widely used cancer drugs, pembrolizumab (sold as Keytruda), costs roughly $4,400 per 100 mg vial and runs about $11,733 per 28-day cycle. Patients on this drug typically receive infusions every three to six weeks, and treatment can continue for a year or longer.
Autoimmune conditions like rheumatoid arthritis, psoriasis, and Crohn’s disease also rely heavily on monoclonal antibodies. Adalimumab, the active ingredient in Humira, had a net price of about $1,812 per dose in 2020 for U.S. commercial and Medicare plans. Since patients inject it every two weeks, annual costs climb quickly. Newer biosimilar versions have started to bring that number down, with the lowest-cost biosimilar formulation listing at $1,558 per dose in 2023.
Some monoclonal antibodies are far less expensive per dose but still add up. Nirsevimab, used to protect infants from respiratory syncytial virus (RSV), runs close to $495 per single dose. Monoclonal antibodies for migraine prevention, which target a pain-signaling protein called CGRP, cost several thousand dollars per quarter in the UK market, with U.S. prices following a similar pattern.
Why These Drugs Cost So Much
Monoclonal antibodies are fundamentally different from the pills you pick up at a pharmacy. Traditional medications are small molecules made through relatively straightforward chemical reactions. Monoclonal antibodies are large, complex proteins grown inside living cells. That cell-based manufacturing is expensive, requiring specialized production lines, extensive purification steps, and temperature-controlled storage and shipping from factory to clinic. A single batch can take weeks to produce.
Development costs are also steep. Bringing a new monoclonal antibody to market involves identifying the right target, engineering the antibody, scaling up cell line production, and running years of clinical trials. Companies price these drugs to recoup that investment during the period of patent exclusivity. Once patents expire, biosimilar competitors can enter the market, but even biosimilar manufacturing requires the same complex cell-based processes, so prices don’t drop as dramatically as they do for generic pills.
How Insurance Covers Monoclonal Antibodies
Coverage depends on how the drug is administered. Monoclonal antibodies given by infusion in a doctor’s office or clinic are typically covered under your medical benefit. For Medicare patients, that means Part B, which requires you to pay 20% of the Medicare-approved amount after meeting the annual deductible. For a cancer drug costing $11,000 a month, that 20% coinsurance alone could mean more than $2,000 per infusion cycle.
Self-injected monoclonal antibodies that you administer at home, like adalimumab for autoimmune conditions, are usually covered under your pharmacy benefit. In Medicare, that falls under Part D. Part D plans can charge between 25% and 33% coinsurance for drugs placed on a specialty tier. After your total out-of-pocket spending crosses an annual threshold, coinsurance drops to 5%, but reaching that threshold can mean paying thousands of dollars in the first months of treatment.
Private insurance varies widely. Many employer-sponsored plans place monoclonal antibodies on specialty tiers with percentage-based coinsurance rather than flat copays. A 20% to 30% coinsurance rate on a drug that costs $5,000 per month can leave you responsible for $1,000 to $1,500 monthly before reaching your plan’s out-of-pocket maximum.
Costs Beyond the Drug Itself
The sticker price of the medication is only part of the bill. If your treatment requires infusion, you’ll also face facility fees from the clinic or hospital where you receive it, plus administration charges for the nursing staff and supplies involved. These fees are billed separately and can add hundreds of dollars per session. Hospital-based infusion centers tend to charge significantly more in facility fees than freestanding infusion centers or doctor’s offices, so where you receive treatment matters.
Some monoclonal antibodies also require regular lab work or imaging to monitor for side effects. Alzheimer’s drugs like lecanemab, for instance, require periodic brain scans. These monitoring costs accumulate over the course of treatment and are often billed under your medical benefit with their own coinsurance.
How Biosimilars Are Lowering Prices
Biosimilars are near-identical versions of original monoclonal antibodies, approved after the originator’s patents expire. Their entry into the market has already started to push prices down. A study spanning 57 countries found that when biosimilars launched, the average price for affected drugs dropped immediately. Bevacizumab (a cancer drug) fell about 25% per dose, infliximab (used for autoimmune diseases) dropped roughly 18%, and trastuzumab (a breast cancer drug) declined nearly 28%.
In the U.S., the impact has been slower but is accelerating. Adalimumab biosimilars entered the market in 2023, with the lowest-cost version listing at a 14% discount compared to what insurers were actually paying for the original product. That gap is expected to widen as more biosimilar manufacturers compete. The savings don’t always reach patients directly, though, because rebate negotiations between drug manufacturers and pharmacy benefit managers can keep the original product financially attractive to insurers even when a cheaper biosimilar exists.
Medicare Price Negotiations
The Inflation Reduction Act gave Medicare the authority to directly negotiate prices on high-cost drugs for the first time. In the third round of selections, CMS chose 15 drugs for negotiation, and several are monoclonal antibodies or biologics: Cosentyx (used for psoriasis and arthritis), Entyvio (for inflammatory bowel disease), Cimzia (for Crohn’s and rheumatoid arthritis), Orencia (for rheumatoid arthritis), and Xolair (for asthma and allergies). This round also marked the first time drugs covered under Part B, the category that includes many infused monoclonal antibodies, were included in negotiations.
Negotiated prices won’t take effect immediately, but when they do, they’ll cap what Medicare pays and reduce coinsurance for enrollees on those specific drugs. For patients currently paying 20% of a high-cost infused biologic, even a modest price reduction could mean hundreds or thousands of dollars in annual savings.
Reducing Your Out-of-Pocket Costs
Most manufacturers of monoclonal antibodies offer patient assistance programs. These take two forms: copay cards for commercially insured patients that can reduce your per-dose cost to as little as $0 to $50, and free drug programs for uninsured or low-income patients. Eligibility for free drug programs typically requires demonstrating financial need based on household income, though specific thresholds vary by manufacturer. Medicare beneficiaries generally cannot use manufacturer copay cards due to federal anti-kickback rules, but they may qualify for separate assistance through independent charitable foundations.
Choosing where you receive infusions can also make a meaningful difference. If your insurer covers treatment at both a hospital outpatient center and a freestanding infusion suite, the freestanding option will almost always cost you less because facility fees are lower. Some insurers now require or incentivize patients to use these lower-cost settings. Ask your provider whether home infusion is an option for your specific drug, as this can further reduce facility-related charges.
If a biosimilar exists for your prescribed monoclonal antibody, ask your doctor whether switching is appropriate. The clinical evidence shows biosimilars perform comparably to the originals, and your out-of-pocket share on a biosimilar can be noticeably lower, particularly if your insurer has placed the biosimilar on a preferred tier.